Dear customers,

Due to the current situation in Germany, the accessibility of our sales team is limited for the next few weeks.
In the city of Halle, all schools and kindergartens were closed as a precautionary action, which also affects employees of the sales team.
If you cannot reach us by phone, please write an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it.

Our production is not affected by the pandemic.

HMC had succsessful days on CPHI in Madrid - the world’s largest pharmaceutical exhibition. From ingredients, fine chemicals and FDF to machinery, packaging, outsourcing and biopharmaceuticals - each pharmaceutical sector is present. CPHI is always the best event to connect all departments of pharma enterprises. More than 2500 exhibitors help to find solutions for each requirement.

HMC is attending CPhI 2018 in Madrid.

We are looking forward to see you there.

Your can meet us from Oct/09 – Oct/11 2018 in Madrid (Spain).

Abstract of the oral presentation at 13th EUCHIS 31st May-3rd June 2017.

More than 2000 publications and 20 published clinical trials within the last 12 month show that chitosan and chitosan derivatives are still attractive for the medical industry. As producer of well defined and pure chitosans and chitosan derivatives for pharmaceutical applications, with more than one hundred different specification for chitosans on the market and around 300 production batches per year HMC is always on the pulse of the market and in contact with regulatories and pharmaceutical companies worldwide.

Media attention for the HMC⁺ - Research. The highly pure Chitosan-products by HMC⁺ are in demand around the world. In addition to our production of highly pure chitosans and chitosan derivatives, we work together with our partners on new applications and other high-tech products.

Katja Richter, CEO of the company join the Family Day 2016 in Bonn. The FD16 (#FD16) is an invitation-only conference from the High-Tech Gründerfonds for networking of Germany’s best founders and CEOs from more than 266 HTGF portfolio companies with well known global players and the venture capital scene in Europe.